RoboCT, a leading Chinese exoskeleton developer, is leveraging its clinical rehabilitation expertise to bring wearable robotic assistive devices into daily life. After raising substantial capital and launching new lightweight models, the company aims to address mobility challenges beyond hospital settings across China’s expanding exoskeleton market.
- China’s exoskeleton market valued at RMB 1.6 billion in 2025
- RoboCT expands from hospital rehab to consumer mobility assistance
- New GoGo exoskeleton launched for lightweight, outdoor use
What happened
RoboCT, a Hangzhou-based company specializing in exoskeleton technology, has broadened its focus from traditional clinical rehabilitation devices to consumer mobility assistance. This shift includes launching the GoGo exoskeleton, a lightweight, battery-free device designed for outdoor walking and everyday use rather than clinical therapy. The company began production of GoGo in mid-2026 at a new facility in Wuxi with initial manufacturing capacity of about 300 units per month.
RoboCT has gained recognition in China as a leading player across medical rehabilitation, consumer assistance, and industrial exoskeleton applications. Their clinical rehabilitation products have secured NMPA regulatory registration and are widely deployed in institutions such as Guangzhou University. The company also recently secured over RMB 100 million in a Series B+ funding round to accelerate domestic and international growth, advance R&D in areas like brain-computer interfaces, and expand distribution channels.
Why it matters
China’s exoskeleton market is rapidly evolving from a primarily medical technology niche to a mass-market sector focused on enhancing everyday mobility. According to IDC’s 2026 report, consumer-assistance exoskeletons now represent over 70% of shipments, signaling increasing demand for usable, multi-purpose wearable robotics outside clinical settings. RoboCT’s development strategy reflects this trend by carrying core clinical-grade technologies into accessible products designed for independent use.
This transition has significant implications for patient independence, elderly mobility, and broader inclusion for those with physical challenges. However, delivering comfortable, user-friendly, and affordable devices remains challenging. Success depends on balancing advanced robotics with ease of wear, reliable performance without clinical supervision, comprehensive training, and strong after-sales support. RoboCT’s approach exemplifies how Chinese startups are shaping a distinct exoskeleton market compared to international peers who remain mostly focused on specialized clinical or industrial uses.
What to watch next
The adoption trajectory of RoboCT’s consumer-oriented exoskeletons like GoGo will be a key indicator of market readiness for wearable mobility assistance in China. Analysts will watch how users respond to factors such as device weight, battery independence, comfort, price, and support infrastructure. Production scale-up and channel expansion in 2026 and beyond will test RoboCT’s ability to convert early clinical success into daily lifestyle integration.
Additionally, advances in related technologies such as brain-computer interfaces and enhancements in sensors and control algorithms may expand the functionality and performance of next-generation devices. RoboCT’s ongoing innovation and regulatory progress will shape China's competitive positioning in the global exoskeleton industry, where different regional players pursue distinct application niches and market strategies.